Fundz Deep Dive
Everything you need to win 3SBio — in one platform.
Who to reach, what to say, and why now on 3SBio — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on 3SBio — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Pfizer Enters $1.25 Billion Agreement with 3SBio for Promising Anti-Tumor Drug.
Jun 23, 2025•12 months ago
Contract Type
agreement
ManufacturingBiotechnology
Description
Pfizer has signed a significant agreement to pay $1.25 billion upfront to 3SBio for rights to a new anti-tumor drug, with total potential worth up to $6.05 billion. This marks a crucial advancement in China's role in global pharmaceutical development.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months